Roche’s CT-388 Phase 2 showed competitive 48-week weight loss. I believe this supports a credible late-entry push into the massive obesity/GLP market. Roche’s Genentech plans to start its Phase 3 this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results